

Cutaquig SCIG Therapy Patient Referral and Prescription

То:	From:	From:		Phone:		
Intake phone: 315.492.1964	Fax:	Fax:		Number of Pages (Including C		over):
Date: DOB:		Aller	gies:	1		
Patient Name:		Heigh	-		Weight:	
 Begin Cutaquig SCIG per KabaFusion protocol formonths Begin Cutaquiggrams SCIG everyformonths KabaFusion to provide infusion pump needle administration sets (A4221) KabaFusion to provide infusion supplies for infusion pump (K0552) KabaFusion to provide mechanical ambulatory infusion pump (E0779) Infusion RN home visit prior to therapy start to assess patient and home environment, educate patient about SCIG therapy. Infusion RN visits x 3 and PRN to educate patient to self administer Cutaquig infusion KabaFusion to provide all professional services related to infusion 						
Diagnosis:						ICD-10
Common Variable Immunodeficiency with Predominant Immunoregulatory T-Cell Disorders						D83.1
Wiskott-Aldrich Syndrome						D82.0
Combined Immunodeficiency, Unspecified						D81.9
Severe Combined Immunodeficiency [SCID] with Low T- and B- Cell Numbers						D81.1
Severe combined Immunodeficiency [SCID] with Low or Normal B-Cell Numbers						D81.2
Selective deficiency of Immunoglobulin A IgA]						D80.2
Selective deficiency of Immunoglobulin M [IgM]						D80.4
Selective deficiency of Immunoglobulin G [IgG] Subclasses						D80.3
Hereditary Hypogammaglobulinemia						D80.0
Immunodeficiency with Increased IgM						D80.5
Other Common Variable Immunodeficiencies						D83.8
Common Variable Immunodeficiency, Unspecified						D83.9
Other:						
Premedication Orders: Refill x 1Year Per KabaFusion recommendation: ACETAMINOPHEN 650 MG (325mg X	?) orally PRE-SCIG	i	Other:		NE 25 MG orally PRE-SCI	G
Prescriber Signature:Date						
Print Prescriber Name:NPI#						
 Please fax the following information: Immunoglobulin order – include dose, route of administration, frequency, duration, and any pre-medications OR use prescription order section above Patient demographics – include insurance information. We will obtain authorization unless the insurance dictates otherwise H & P OR progress note(s) describing diagnosis and clinical status Labs – BUN/Creatinine (preferred within last 90 days), Immunoglobulin Panel 						
document, and the recipient of such information is subject to obligations of secrecy to and for the benefit of KabaFusion Holdings, LLC. Any unauthorized use or disclosure of such information is strictly prohibited. This message, together with any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain information that is confidential and prohibited from disclosure. If you are not the intended recipient, you are hereby notified that any dissemination, or copying of this message, or any attachment, is strictly prohibited. If you have received this message in error, please notify the original sender immediately by telephone or by return fax and shred this document along with any other documents. Thank you.						
KabaFusion Infusion Pharmacy 922 Spencer Street Syracuse, NY 13204 Phone: 315.492.1964 Fax: 315.469.9744 <u>www.kabafusion.com</u>						